Fetalix has been selected as a winner of the latest edition of STARTUP Lab, a programme designed to support early-stage ventures through mentorship, training, and investor-oriented feedback.
The programme provided access to experienced mentors and industry experts, enabling participating teams to refine their value proposition, strengthen their communication strategy, and improve their understanding of market and investment expectations within the innovation ecosystem.
Beyond training and networking, initiatives like STARTUP Lab play a key role in de-risking early-stage startups by helping them align scientific innovation with clear business and translational pathways. This recognition supports Fetalix’s continued development as a science-driven biotechnology company and reinforces its trajectory in advancing regenerative solutions for intervertebral disc degeneration and low back pain.
October 30, 2024
